173 results about "Peptoid" patented technology

The present invention provides spreading agents based on sequence-specific oligomers comprising a peptoid, a peptide-peptoid chimera, a retropeptoid or a retro(peptoid-peptide) chimera, and methods for using the same, including for the treatment of respiratory distress of the lungs. The spreading agents are sequence-specific oligomers, including retrosequence-specific oligomers, based on a peptide backbone, that are designed as analogs of surfactant protein-B or surfactant protein-C.

Immobilizable antimicrobial compounds incorporating antimicrobial and / or antifouling components, as can be adhered to various device structures and components.

The invention describes a method for determining aggregation in protein, peptide or peptoid formulation, without the use of probes or additives. The method uses FTIR spectroscopy combined with the two-dimensional correlation analysis (2DCOS) which allows for the determination of the presence of aggregates, the determination of the mechanism of aggregation, allowing for correction in the pipeline manufacturing process of the protein to once again generate viable protein. In addition, the thermal transition of the protein can also be determined and a 2DCOS plot generated to compare with the established viable protein, allowing for quality control, stability and viability of the desired protein product. The ease of sample preparation and data analysis allows for the automation of this method.

The present invention provides for the identification of autoreactive T cell populations from individuals having autoimmune diseases, such as multiple sclerosis and EAE. Peptoids recognized by autoreactive T cells can be used to identify various types of autoimmune disease, and can also be used to target therapies against such populations.

Novel peptoid oligomers are disclosed that have a formula represented by the following formula I:The peptoids demonstrate antimicrobial activity and may be prepared as pharmaceutical compositions and used for the prevention or treatment of a variety of conditions in mammals including humans where microbial invasion is involved. The present cyclic and linear peptoids are particularly valuable as their effect is rapid, broad in spectrum and mostly indifferent to resistance provoked by standard antibiotics.

A cell-based screen is reported can be used to identify specific receptor-binding compounds in a combinatorial library of peptoids (N-alkylglycine oligomers) displayed on beads. This strategy was applied to the isolation of Vascular Endothelial Growth Factor Receptor 2 (VEGFR2)-binding peptoids, which were optimized to create lead compounds with high affinity for VEGFR2. One of these peptoids was shown to be an antagonist of VEGF-VEGFR2 interaction and receptor function.

Peptoid compounds of Formula I and Formula II are disclosedThe compounds are useful in the treatment of matrix metalloproteinase-mediated disorders.

The present invention relates to hydrogels comprising a plurality of amphiphilic peptides and / or peptoids capable of self-assembling into three-dimensional macromolecular nanofibrous networks, which entrap water and form said hydrogels, wherein at least a portion of said plurality of amphiphilic peptides and / or peptoids is chemically cross-linked. The present invention further relates to methods for preparing such hydrogels and to various uses of such hydrogels, e.g. as cell culture substrates, for drug and gene delivery, as wound dressing, as an implant, as an injectable agent that gels in situ, in pharmaceutical or cosmetic compositions, in regenerative medicine, in tissue engineering and tissue regeneration, or in electronic devices. It also relates to a method of tissue regeneration or tissue replacement using a hydrogel in accordance with the present invention.

The present invention provides an amphiphilic linear peptide and / or peptoid as well as a hydrogel that includes the amphiphilic linear peptide / peptoid.

The present invention provides an amphiphilic linear peptide and / or peptoid as well as a hydrogel that includes the amphiphilic linear peptide / peptoid. The amphiphilic linear peptide / peptoid is capable of forming a hydrogel. These peptides / peptoids include short amphiphilic sequences with a hydrophobic portion of aliphatic amino acids and at least one acidic, neutral, or basic polar amino acid. The amphiphilic linear peptide / peptoid is build up of non repetitive aliphatic amino acids, which may be in the L- or D-form. A plurality of such peptides / peptoids assembles to supramolecular helical fibers and forms peptide hydrogels after assembly. A corresponding hydrogel is formed in aqueous solutions at physiological pH and is thus useful for inter alia cell culture, tissue engineering, and drug release. Such hydrogels which are rigid, biocompatible and entrapping up to 99.9% of water are also well suited for applications utilizing electronic devices.

The present invention provides a primer that effectively can detect, for example, the double helix structure of a nucleic acid. The primer is a labeled nucleic acid containing at least one structure represented by the following formula (16),where B is an atomic group having a nucleobase skeleton, E is an atomic group having a deoxyribose skeleton, a ribose skeleton, or a structure derived from either one of them, or an atomic group having a peptide structure or a peptoid structure, and Z11 and Z12 are each an atomic group that exhibits fluorescence and are identical to or different from each other.

The present invention relates to peptides, nucleic acids, and cells for use in the immunotherapy of cancer. The present invention furthermore relates to survivin-derived tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention specifically relates to three novel peptide sequences and variants thereof derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.

Embodiments of the invention are directed to a one-bead-two-compound method for the creation of encoded cyclic peptoid libraries. This scheme is useful for the creation of cyclic peptoid microarrays since only the cyclic peptoid, not the linear encoding molecule, contains an attachment residue and thus can be spotted onto an activated substrate.

The invention provides a peptoid inhibitor as well as a preparation method and application thereof, relates to the technical field of biomedicine and specifically relates to a peptoid, in particular to a polypeptide-aggregated peptoid inhibitor capable of inhibiting Abeta1-42. The peptoid inhibitor is prepared from Npip, Nmba, Nlys and Nleu subunits. The peptoid inhibitor API 1 is an inhibitor which is high in water solubility, low in cytotoxicity and high in associative property with beta-islet amyloid polypeptide, thereby providing a new selection for researching medicaments for treating Alzheimer's disease.

The invention provides a peptoid as well as a preparation method and application thereof. The peptoid comprises the following subunits: ethylenediamine (I), piperonylamine (II), beta-alanine (III), 1-naphthylamine (IV) and cysteine (V). The peptoid is simple in synthesis, has strong combining capacity with alpha-synuclein, can effectively screen the serum of PD patients and able-bodied persons through alpha-synuclein in the serum, and provides a novel liquid biopsy method and concept for diagnosis and monitoring of the Parkinson's disease.

Molecules having potential biological activity, particularly peptoids, that are conjugated to solid phase supports, spacer groups, and / or ligation moieties, and methods of their preparation, are described. In some instances, the molecules of the invention are made entirely by solid phase synthesis. In other instances, the spacer groups are hydrophilic and compositions containing them, and to solid phase synthesis of varied structure peptoids using chemoselective ligation moieties.

The invention provides a carbamido peptide aminopeptidase N inhibitor and application thereof. The invention provides the superactive peptide aminopeptidase N inhibitor, thereby being capable of curing the disease that the activity or the express of the aminopeptidase N is abnormal. Specifically, the invention relates to a peptide compound with the structures of general formulas (I), (II) or (III), and further relates to various optical isomers thereof, a pharmaceutically acceptable salt, a solvate and a prodrug. The invention further relates to a drug composite of the peptide compound which comprises the structures of the general formulas (I), (II) or (III) and use therefore for preparing the drug.

Compounds of Formulas I:and shorter variants thereof are described, along with solid supports having such compounds coupled thereto, and the use thereof as affinity ligands for antibodies.

The present invention relates to the use of peptides, peptoids and / or peptidomimetics capable of self-assembling and forming a (nanofibrous) hydrogel in biofabrication. The present invention further relates to methods for preparing hydrogels and to methods for preparing continuous fibres and to methods for obtaining multi-cellular constructs with defined, precise geometrics. The present invention further relates to various uses of such hydrogels for obtaining mini-hydrogel arrays and 3D organoid structures or 3D macromolecular biological constructs.

The present invention provides an amphiphilic linear peptide and / or peptoid as well as a hydrogel that includes the amphiphilic linear peptide / peptoid.

The present invention provides, for example, a labeling substance that allows the double helix structure of a nucleic acid to be detected effectively. The present invention provides a compound having a structure derived from mononucleoside or mononucleotide, with the structure being represented by the following formula (1), (1b), or (1c), a tautomer or stereoisomer thereof, or a salt thereof.In the above formulae, B is an atomic group having a nucleobase skeleton, E is an atomic group having a deoxyribose skeleton, a ribose skeleton, or a structure derived from either one of them, or an atomic group having a peptide structure or a peptoid structure, and Z11 and Z12 each are a hydrogen atom, a protecting group, or an atomic group that exhibits fluorescence and may be identical to or different from each other.

The present invention provides, for example, a labeling substance that allows the double helix structure of a nucleic acid to be detected effectively. The present invention provides a compound having a structure derived from mononucleoside or mononucleotide, with the structure being represented by the following formula (1), (1b), or (1c), a tautomer or stereoisomer thereof, or a salt thereof.In the above formulae, B is an atomic group having a nucleobase skeleton, E is an atomic group having a deoxyribose skeleton, a ribose skeleton, or a structure derived from either one of them, or an atomic group having a peptide structure or a peptoid structure, and Z11 and Z12 each are a hydrogen atom, a protecting group, or an atomic group that exhibits fluorescence and may be identical to or different from each other.

The invention provides synthesis for biodegradable amphiphilic block copolymerization antibacterial peptoids, a preparation method of antibacterial peptoid vesicles and applications of the antibacterial peptoid vesicles. The synthesis for the antibacterial peptoids comprises the following steps: a hydrophilic polypeptide chain segment containing an amino protective group, a hydrophobic polymer chain segment of which one end is amino-terminated and isocyanate radicals of a diisocyanate unit are connected through covalent bonds, and therefore the antibacterial peptoids are obtained; and the antibacterial peptoid vesicles are formed by self assembly of the antibacterial peptoids, and the antibacterial peptoid vesicles can be used as antibacterial agents or drug carriers to be applied to aspects such as clinical inflammation resistance, anti-cancer drug targeting release, or nanomedicine. The antibacterial peptoid vesicles select and use the biodegradable hydrophobic polymer chain segment to replace a hydrophobic amino acid chain segment in an antibacterial peptide, thus the antibacterial peptoid vesicles do not have cytotoxicity, and have excellent biocompatibility and biodegradability; and besides, the antibacterial peptoid vesicles have a broad-spectrum antibacterial property, and a membrane damage antibacterial mechanism which is similar to that of a natural antibacterial peptide, and therefore drug tolerance of germs is not easily induced.

The present invention provides an amphiphilic linear peptide and / or peptoid as well as a hydrogel that includes the amphiphilic linear peptide / peptoid. The amphiphilic linear peptide / peptoid is capable of forming a hydrogel. These peptides / peptoids include short amphiphilic sequences with a hydrophobic portion of aliphatic amino acids and at least one acidic, neutral, or basic polar amino acid. The amphiphilic linear peptide / peptoid is build up of non repetitive aliphatic amino acids, which may be in the L- or D-form. A plurality of such peptides / peptoids assembles to supramolecular helical fibers and forms peptide hydrogels after assembly. A corresponding hydrogel is formed in aqueous solutions at physiological pH and is thus useful for inter alia cell culture, tissue engineering, and drug release. Such hydrogels which are rigid, biocompatible and entrapping up to 99.9% of water are also well suited for applications utilizing electronic devices.

The invention relates to peptoid reagents that interact preferentially with a pathogenic form of a conformational disease protein as compared to a nonpathogenic form of the conformational disease protein where the peptoid reagent comprises an amino-terminal region, a carboxy-terminal region, and at least one peptoid region between the amino-terminal region and the carboxy-terminal region where the peptoid region comprises 3 to about 30 N-substituted glycines, and optionally one or more amino acids. The invention also relates to methods of using the peptoids in detecting and isolating prions, and in the treatment and prevention of prion-related diseases.

The present invention relates to hydrogel membranes comprising a hydrogel, said hydrogel comprising a plurality of tetramer amphiphilic peptides and / or peptoids capable of self-assembling into three-dimensional macromolecular nanofibrous networks, which entrap water and form said hydrogels, wherein at least a portion of said plurality of tetramer amphiphilic peptides and / or peptoids is chemically cross-linked. The present invention further relates to stratisfied biostructures and devices comprising at least two hydrogel membranes of the invention, which can be used e.g. to rebuild human skin and for tissue engineering of organs and tissues. The present invention further relates to corneal implants and devices comprising a hydrogel membrane of the invention.